Business Context and Reporting Period
This Form 8-K, dated May 8, 2026, reports the completion of a tender offer and subsequent merger by Aurinia Pharmaceuticals Inc. (the "Parent") to acquire Kezar Life Sciences, Inc. (the "Company"). The transaction was finalized on May 8, 2026, with the legal merger consummated on May 11, 2026.
Key Financial Metrics and Transaction Terms
- Offer Price: $6.955 in cash per share plus one Contingent Value Right (CVR).
- Shares Tendered: 5,927,580 shares validly tendered and not withdrawn.
- Ownership Percentage: Approximately 80.24% of outstanding shares were tendered, satisfying the Minimum Tender Condition.
- Equity Treatment: In-the-money stock options were converted to cash (excess of cash amount over exercise price) plus one CVR per underlying share. Out-of-the-money options were cancelled without consideration.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for either entity.
Material Changes
The primary material change is the change in corporate control. Kezar Life Sciences, Inc. is now a wholly-owned subsidiary of Aurinia Pharma U.S., Inc. The separate corporate existence of the merger subsidiary ceased, and Kezar continues as the surviving corporation. The Company's 2018 Employee Stock Purchase Plan was terminated immediately prior to the effective time of the merger.
Outlook, Risks, and Contingencies
- Contingent Value Rights (CVRs): Shareholders and option holders received CVRs representing the right to potential future payments subject to conditions outlined in the CVR Agreement dated May 11, 2026.
- Appraisal Rights: Shareholders who properly exercised appraisal rights under Delaware law did not receive the Offer Price.
- Regulatory Compliance: The merger was completed pursuant to Section 251(h) of the Delaware General Corporation Law, requiring no stockholder vote.
Investor Verification Checklist
- Verify the specific milestones and payment terms within the Contingent Value Rights (CVR) Agreement (Exhibit 2.2).
- Confirm the final cash consideration received for tendered shares and in-the-money options.
- Review the full text of the Merger Agreement (Exhibit 2.1) for any omitted annexes or schedules regarding transaction conditions.
- Monitor future filings for the integration of Kezar's operations and financial results into Aurinia's consolidated reports.